Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I

This study has been completed.
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by:
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00071656
First received: October 29, 2003
Last updated: August 6, 2013
Last verified: August 2013
History of Changes
  Purpose
The purpose of this study is to develop and implement a treatment that focuses on behaviors to reduce symptom severity and functional impairment in patients with Attention Deficit Hyperactivity Disorder, Predominantly Inattentive Type (ADHD-I). The long-term goal of this study is to apply the treatment to larger-scale trials to determine its effectiveness and generalizability.

Condition Intervention
Attention Deficit Disorder With Hyperactivity
 Behavioral: Psychosocial (behavioral) Intervention

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: Psychosocial Treatment for ADHD Inattentive Type I

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of California, San Francisco:
Estimated Enrollment: 60
Study Start Date: September 2002
Study Completion Date: June 2007
Detailed Description:

ADHD-I is a highly prevalent and serious childhood disorder that affects academic and social development. The symptoms of ADHD-I differ from those of the well-studied ADHD Combined Type. Unfortunately, studies of psychosocial interventions for ADHD-I are currently unavailable. Effective treatments for ADHD-I are still needed.

Participants are randomly assigned to receive either a behavioral intervention or treatment as usual for 10 to 12 weeks. The behavioral intervention includes parent and child skill development groups, family meetings, and consultation with the child's teacher to address attention problems and areas of impairment at home and school. Parent and child interviews, teacher and child ratings, and psychoeducational testing are used to assess participants. Participants are assessed post-treatment and at a 2-month follow-up visit.

  Eligibility
Ages Eligible for Study:   7 Years to 11 Years   (Child)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ADHD, Predominantly Inattentive Type
  • Public or private school attendance
  • English speaking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00071656

Locations
United States, California
HALP Clinic, Children's Center at Langley Porter, UCSF
San Francisco, California, United States, 94143
Sponsors and Collaborators
University of California, San Francisco
National Institute of Mental Health (NIMH)
  More Information

ClinicalTrials.gov Identifier: NCT00071656     History of Changes
Other Study ID Numbers: R21MH065927  DSIR CT-S 
Study First Received: October 29, 2003
Last Updated: August 6, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
 Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on September 27, 2016